286-300 of 379
Patient Case: ATTRwt-CM Discovered Decades After Heart Transplant
Heart MattersPatient Case: ATTRwt-CM Discovered Decades After Heart Transplant
Lily Stern, MD
Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
Project Oncology®Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
Developments in Duchenne Muscular Dystrophy Care: Examining the Options
NeuroFrontiersDevelopments in Duchenne Muscular Dystrophy Care: Examining the Options
Differentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
NeuroFrontiersDifferentiating gMG for Diagnostic Precision: The Role of Fatigable Weakness
Maxwell H. Levy, MD
Silent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Spotlight On ATTR-CMSilent Brain Damage in ATTR-CM: Exploring Neurological Impacts
Vutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
Spotlight On ATTR-CMVutrisiran for ATTR-CM: Exploring an RNAi Therapeutic
- advertisement
Exercise in Multiple Myeloma: Balancing Benefits and Safety
Project Oncology®Exercise in Multiple Myeloma: Balancing Benefits and Safety
Jens Hillengass, MD, PhD
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
NeuroFrontiersRozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
Gil I. Wolfe MD, FAAN
Challenges in DMD: Understanding the Height Factor
NeuroFrontiersChallenges in DMD: Understanding the Height Factor
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Project Oncology®Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
NKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
NeuroFrontiersNKX019: A Potential New Frontier in Generalized Myasthenia Gravis Therapy
Diagnosing IgAN: The Importance of Early and Accurate Identification
Clinician's RoundtableDiagnosing IgAN: The Importance of Early and Accurate Identification
James Chevalier, MD
- advertisement
Investigating the Incidence of IgA Nephropathy Among Racial and Ethnic Groups
Clinician's RoundtableInvestigating the Incidence of IgA Nephropathy Among Racial and Ethnic Groups
John Sim, MD
Diagnosing Castleman Disease: Key Considerations
Project Oncology®Diagnosing Castleman Disease: Key Considerations
Mateo Bustamante
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Project Oncology®Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
Joshua Brandstadter, MD, PhD, MSc